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Background: Everolimus-eluting stents (EES) improve clinical outcome compared to early generation paclitaxel-eluting stents (PES) and sirolimus-
eluting stents (SES). It remains unclear whether this advantage is sustained in diabetic patients during long-term follow-up.
Methods: Between 2002 and 2009, a total of 2121 diabetic patients treated with the unrestricted use of EES (n=807), SES (n=696), or PES 
(n=618) were systematically followed throughout three years for the occurrence of cardiac events at two academic institutions. The primary endpoint 
was a composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR).
Results: The primary outcome occurred in 18.0% of EES, 20.9% of SES and 21.4% of PES treated patients ([EES vs. SES] aHR=0.91, 95%CI 
0.79-1.04; [EES vs. PES] aHR=0.76, 95%CI 0.58-1.00). EES patients had significantly less TLR compared to SES and PES patients ([EES vs. SES] 
aHR=0.68, 95%CI:0.55-0.83; [EES vs. PES] aHR=0.51, 95%CI:0.33-0.77). While the risk of definite stent thrombosis (ST) was significantly lower with 
EES (0.3%) as compared to SES (3.3%) and PES (3.8%) (aHR [EES vs. SES]=0.53, 95%CI 0.35-0.82; aHR [EES vs. PES]=0.28, 95%CI:0.12-0.65), 
there were no significant differences in all-cause mortality, cardiac mortality or myocardial infarction.
Conclusion: In diabetic patients, the unrestricted use of EES appears to significantly decrease the need for TLR and ST compared to early 
generation SES and PES throughout 3-years follow-up.
 
